sugar levels should tell their doctor. The infusion of ORENCIA contains
maltose, a sugar that can give falsely high blood glucose readings with
some monitors on the day the infusion is received. The doctor may recommend
a different monitor.
Women who are pregnant, planning to become pregnant or are thinking
about becoming pregnant should tell their doctor. It is not known if
ORENCIA(R) (abatacept) can harm an unborn baby. Women who are breast
feeding should also inform their doctor. They will need to decide to either
breast-feed or receive treatment with ORENCIA, but not both.
Important Information about Side Effects with ORENCIA
Like all medicines that affect your immune system, ORENCIA can cause
serious side effects. The possible serious side effects include serious
infections and allergic reactions. Also, rare cases of certain kinds of
cancers have been reported.
People taking ORENCIA are at increased risk for developing infections
including pneumonia, and other infections caused by viruses, bacteria, or
fungi. Individuals should call their doctor immediately if they feel sick
or get any infection during treatment with ORENCIA.
Allergic reactions are usually mild or moderate, generally occur within
the first 24 hours of an infusion, and include hives, swollen face,
eyelids, lips, tongue, throat, or trouble breathing. There have been some
serious allergic reactions reported after receiving an infusion of ORENCIA.
There have been rare cases of certain kinds of cancer. The role of
ORENCIA in the development of cancer is not known.
The more common side effects with ORENCIA are headache, upper
respiratory tract infection, sore throat, and nausea.
For Full Prescribing Information, please visit http://www.ORENCIA.com or
Dosing and Administration
ORENCIA is administered by a healthcare pr
Page: 1 2 3 4 Related medicine technology :1
|SOURCE Bristol-Myers Squibb Company|
Copyright©2007 PR Newswire.
. Investigational Study Demonstrated a Re-Establishment of Clinical
Improvement with Orencia (Abatacept) in Children with Juvenile
Idiopathic Arthritis upon Re-Introduction of Therapy2
. Advanced Life Sciences Announces Supplemental Efficacy Data from
First Pivotal Phase 3 Pneumonia Clinical Trial3
. Materia Licenses Metathesis Catalyst Platform to Eisai4
. Vical Licensee AnGes MG Announces Positive Results of Phase 3
Angiogenesis Trial in Japan5
. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07
Teleconference to Answer Questions About TA-65, Their Telomerase
Activator With Proven Age Management Benefits6
. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets
Phase II Study Endpoints of Immunogenicity and Safety Compared to
. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively
Licensed to Subsidiary, RXi Pharmaceuticals, Described in
. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR9
. New Quality Control Systems for Every Laboratory Application10
. Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor
AP 12009 to be Presented11
. Antares Pharma Announces Positive Results from Application Site
Study for Anturol